Genovate Aims For Global Insulin Position Under $1bn Project
This article was originally published in PharmAsia News
Genovate has begun construction of its first manufacturing facility for insulins as part of a total investment of $1bn and with the ambition to become China’s first, and the world's fourth largest, manufacturer of insulin using efficient and ecologically friendly production technology.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.